Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20201110049334N1
IRCT20201110049334N1
Completed
Phase 3

Evaluation of estrogen therapy on final height of short girls with chronic kidney disease (CKD) and delayed puberty

Iran University of Medical Sciences0 sites75 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
75
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patient and parent consent to participate in the study.
  • •Patients with chronic kidney disease (CKD).
  • •Patients must be girls.
  • •With short stature (height and growth velocity respectively below 3th and 25th percentile for more than 1 year).
  • •In all patients, beginning of dialysis around 3\.5 to 5 years.
  • •Growth hormone has been started in all patients from the age of 5\.5 to 8 years, despite therapeutic indications.

Exclusion Criteria

  • •Incidence puberty before the estrogen therapy
  • •Kidney transplantation before the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
The use of estrogen pretreatment before starting controlled ovarian stimulation in antagonist protocol.Fertility-femaleInfertile women undergoing ICSI
PACTR201307000566378Hassan Aly Hassan Elmeghraby400
Completed
Not Applicable
Benefit of giving estrogen in IVF cycles.Health Condition 1: null- Infertile patients undergoing IVF
CTRI/2017/10/010083Maulana Azad Medical College and Lok Nayak Hospital150
Recruiting
Not Applicable
A clinical trial to study the effects of estradiol as compared to EMLA cream on pain due to puncturing the vein and easiness during inserting cannula in obese female patients.Health Condition 1: null- Pts of ASA I& II,Female pts undergoing any elective surgery,Age between 25 -65 years,Body Mass Index 30kg/mt2,Hemodynamically stable.
CTRI/2014/11/005162A132
Active, not recruiting
Not Applicable
The fase II study evaluates the safety and efficacy of treatment with low doses of topical vaginal estrogen in pre- and postmenopausal patients with breast cancer and urogenital symptoms related to adjuvant hormone therapyPre- and postmenopausal women who are receiving adjuvant endocrine treatment (LH-RH analogue plus Tamoxifene or Aromatase Inhibitor, Tamoxifene alone, Aromatase Inhibitor alone) for early breast cancer.MedDRA version: 14.1Level: LLTClassification code 10006283Term: Breast neoplasm malignant femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2010-024603-26-ITISTITUTO EUROPEO DI ONCOLOGIA67
Completed
Phase 2
Effects of estrogen on prognosis of patient with diffuse axonal injury due to severe traumatic brain injury
IRCT2014091919227N1Vice chanscellor for research, Tabriz University of Medical Sciences